Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 62.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 0 · 0%High 1 · 12.5%

Rufinamide plus ASMs vs placebo plus ASMs

Seizure freedom · Lennox‐Gastaut syndrome, any age

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rufinamide plus ASMs vs placebo plus ASMs

Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rufinamide plus ASMs vs placebo plus ASMs

50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age

Rufinamide plus ASMs leads to higher number of participants with ≥ 50% reduction in all seizures compared with placebo plus ASMs (high certainty).

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
RR 2.84 [1.31, 6.18]
1 study · 138 participants
High

Rufinamide plus ASMs vs placebo plus ASMs

Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age

Rufinamide plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
RR 4.14 [0.49, 34.86]
1 study · 59 participants
Low

Rufinamide plus ASMs vs other ASM plus ASMs

Seizure freedom · Lennox‐Gastaut syndrome, any age

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rufinamide plus ASMs vs other ASM plus ASMs

Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rufinamide plus ASMs vs other ASM plus ASMs

50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age

The review found no eligible studies for this question.

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rufinamide plus ASMs vs other ASM plus ASMs

Number of adverse events requiring discontinuation of treatment ‐ not reported · Lennox‐Gastaut syndrome, any age

Rufinamide plus ASMs showed no clear difference in number of participants with treatment‐emergent adverse events… compared with other ASM plus ASMs (low certainty).

1 finding from 1 review

Anti‐seizure medications for Lennox‐Gastaut syndrome 2021 · Cochrane Headline outcomes only
RR 0.96 [0.1, 9.57]
1 study · 37 participants
Low